Why the study?
Immune checkpoint inhibitor-associated myocarditis often presents with a severe phenotype and high fatality rate, while diagnosis remains challenging and treatment algorithms are still evolving.
This review summarizes current diagnostic and therapeutic algorithms for immune checkpoint inhibitor-related myocarditis and highlights the need for better risk stratification and multicenter registries.
Answers are grounded in this paper and cite their sources.
Requires heightened vigilance for early ICI myocarditis given high fatality; leaves open standardized diagnostic and treatment algorithms.
INTRODUCTION: Myocarditis associated with immune checkpoint inhibitors presents with an often-severe clinical phenotype with arrhythmias and concurrent myositis. This condition tends to occur early after treatment onset and is associated with a high fatality rate. Diagnosis may be challenging, and treatment algorithms are still evolving. AREAS COVERED: This review will provide an overview of immune checkpoint inhibitor mechanism of action and how it relates to myocarditis pathophysiology, diagnostic algorithms and potential pitfalls, and emerging treatment approaches published until May 2023. We will focus on the state of the field and potential new directions in research and patient care. We will also provide consensus-based diagnostic and therapeutic algorithms endorsed by major societies. EXPERT OPINION: The field needs more evidence-based approaches to risk stratification so that therapy can be tailored toward less cardiotoxic alternatives in high-risk patients. For diagnostic and therapeutic approaches, data from animal models are unlikely to provide conclusive evidence given the complexity of the human immune system. We strongly invite practitioners in the field to contribute every case to the ongoing multicenter registries.
No takes yet. Share an insight, caveat, or question.
Turker et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: